Press release
Hyperphosphatemia Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Gran
Hyperphosphatemia Pipeline
In the Hyperphosphatemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hyperphosphatemia NDA approvals (if any), and product development activities comprising the technology, Hyperphosphatemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Hyperphosphatemia Pipeline treatment landscape of the report, click here @ Hyperphosphatemia Pipeline Outlook- https://www.delveinsight.com/report-store/hyperphosphatemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Hyperphosphatemia Pipeline Report
• DelveInsight's Hyperphosphatemia Pipeline analysis depicts a robust space with 15+ active players working to develop 15+ pipeline treatment therapies.
• The leading companies are working in the Hyperphosphatemia market include PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Grand Nuokang Biopharmaceutical Co., Ltd., Chugai Pharmaceutical, Keryx Biopharmaceuticals, Panion & BF Biotech Inc., Sinomune Pharmaceutical, Daiichi Sankyo, J-Pharma, OPKO Renal, Altair Nanotechnologies, China Nuokang Bio-Pharmaceutical, Unicycive Therapeutics, and others.
• Promising Hyperphosphatemia Pipeline Therapies in the various stages of development include PT20, Fosrenol (Lanthanum Carbonate, BAY77-1931), KHK7791, VS-505, Sevelamer Carbonate, and others.
• On August 2023, Kyowa Kirin Co Ltd announced a study of phase 3 clinical trials for KHK7791. To investigate the safety of repeated administration of KHK7791 for 52 weeks while switching from a phosphate-binding agent to KHK7791 in Hemodialysis patients with hyperphosphatemia.
Hyperphosphatemia Overview
Hyperphosphatemia-that is, abnormally high serum phosphate levels-can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. However, even severe hyperphosphatemia is for the most part clinically asymptomatic.
For further information, refer to the detailed Hyperphosphatemia Unmet Needs, click here for Hyperphosphatemia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/hyperphosphatemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hyperphosphatemia Emerging Drugs Profile
• FC818 (ferric citrate): PUMC Pharmaceutical
FC818 is a novel non-calcium-based phosphate binder. One Phase I and two pivotal Phase II clinical trials showed FC818 to be an effective and safe treatment for lowering and/or maintaining serum phosphorus levels
• VS 505: Shanghai Alebund Pharmaceuticals
VS 505 is a phosphate binding modulator being developed by Shanghai Alebund Pharmaceuticals for the treatment of Hyperphosphataemia. The drug is currently in phase II of clinical trials.
Hyperphosphatemia Pipeline Therapeutics Assessment
There are approx. 15+ key companies which are developing the therapies for Hyperphosphatemia. The Hyperphosphatemia companies which have their Hyperphosphatemia drug candidates in the most advanced stage, i.e. phase III include, PUMC Pharmaceutical.
Request a sample and discover the recent advances in Hyperphosphatemia Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Hyperphosphatemia Segmentation- https://www.delveinsight.com/sample-request/hyperphosphatemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Hyperphosphatemia Drugs and Companies
• PA21: Kissei Pharmaceuticals
• Tenapanor: Ardelyx
• VS-505: Shanghai Alebund Pharmaceuticals Limited
Hyperphosphatemia Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Hyperphosphatemia Therapeutics Market include-
PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Grand Nuokang Biopharmaceutical Co., Ltd., Chugai Pharmaceutical, Keryx Biopharmaceuticals, Panion & BF Biotech Inc., Sinomune Pharmaceutical, Daiichi Sankyo, J-Pharma, OPKO Renal, Altair Nanotechnologies, China Nuokang Bio-Pharmaceutical, Unicycive Therapeutics, and others.
Dive deep into rich insights for drugs for Hyperphosphatemia Pipeline, click here @ Hyperphosphatemia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/hyperphosphatemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Hyperphosphatemia Pipeline Report
• Coverage- Global
• Hyperphosphatemia Companies- PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Grand Nuokang Biopharmaceutical Co., Ltd., Chugai Pharmaceutical, Keryx Biopharmaceuticals, Panion & BF Biotech Inc., Sinomune Pharmaceutical, Daiichi Sankyo, J-Pharma, OPKO Renal, Altair Nanotechnologies, China Nuokang Bio-Pharmaceutical, Unicycive Therapeutics, and others.
• Hyperphosphatemia Therapies- PT20, Fosrenol (Lanthanum Carbonate, BAY77-1931), KHK7791, VS-505, Sevelamer Carbonate, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Hyperphosphatemia Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/hyperphosphatemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Hyperphosphatemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hyperphosphatemia - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Hyperphosphatemia Collaboration Deals
9. Late Stage Products (Phase III)
10. FC 818: PUMC Pharmaceutical
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. VS 505: Shanghai Alebund Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Hyperphosphatemia Key Companies
17. Hyperphosphatemia Key Products
18. Hyperphosphatemia- Unmet Needs
19. Hyperphosphatemia- Market Drivers and Barriers
20. Hyperphosphatemia- Future Perspectives and Conclusion
21. Hyperphosphatemia Analyst Views
22. Hyperphosphatemia Key Companies
23. Appendix
Trending Reports:
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Ambulatory Arrhythmia Monitoring Devices Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Cardiopulmonary Bypass Equipment Market: https://www.delveinsight.com/report-store/cardiopulmonary-bypass-equipment-market
• Chemotherapy Induced Anemia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-market
• Chronic Bronchitis Market: https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-market
• Clbp Market: https://www.delveinsight.com/report-store/chronic-lower-back-pain-clbp-market
• Hearing Implants Market: https://www.delveinsight.com/report-store/hearing-implants-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Pemphigus Vulgaris Market: https://www.delveinsight.com/infographics/pemphigus-vulgaris-market
• Polycythemia Vera Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Airway Stent Market Market: https://www.delveinsight.com/report-store/airway-stent-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alport Syndrome Market: https://www.delveinsight.com/report-store/alport-syndrome-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Bladder Pain Syndrome Market: https://www.delveinsight.com/report-store/interstitial-cystitis-market
• Bone Densitometers Market: https://www.delveinsight.com/report-store/bone-densitometers-market
• Brain Aneurysm Stents Market: https://www.delveinsight.com/report-store/brain-aneurysm-stents-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-market
• Chronic Inflammatory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Inflammtory Demyelinating Polyneuropathy Market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myeloid-leukemia-market
• Cutaneous T-cell Lymphoma Market: https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Dermal Erythema Market: https://www.delveinsight.com/report-store/dermal-erythema-market
• Eczema Market: https://www.delveinsight.com/report-store/atopic-dermatitis-market
Contact Info:
Ankit Nigam
Assistant Manager (Marketing & Branding)
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hyperphosphatemia Pipeline Assessment 2024: Clinical Trials, FDA Approvals, Therapies, ROA, MOA and Key Companies involved by DelveInsight | PUMC Pharmaceutical, Shanghai Alebund Pharmaceuticals, Ardelyx, Kyowa Kirin, Phosphate Therapeutics, Liaoning Gran here
News-ID: 3469032 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Hyperphosphatemia
Hyperphosphatemia Market to Reach USD 10.3 Billion by 2034
Hyperphosphatemia is a metabolic disorder characterized by abnormally elevated phosphate levels in the blood, most often associated with chronic kidney disease (CKD) and end-stage renal disease (ESRD). When kidneys fail to excrete phosphate efficiently, it accumulates, leading to vascular calcification, bone disorders, and increased cardiovascular risk.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71967
It remains a major complication in CKD and dialysis patients, making phosphate control a critical component…
Key Trends Reshaping the Hyperphosphatemia Treatment Market: Rising Emphasis On …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Hyperphosphatemia Treatment Market Size Growth Forecast: What to Expect by 2025?
The market size for hyperphosphatemia treatment has seen a swift expansion in the recent past. The projected growth is from $4.56 billion in 2024 to $5.08 billion in 2025, reflecting a compound annual growth rate (CAGR) of 11.4%.…
Sustainable Growth Of Hyperphosphatemia Treatment Market Amid Rising Chronic Dis …
Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.
What Will the Hyperphosphatemia Treatment Industry Market Size Be by 2025?
The market for hyperphosphatemia treatment has expanded quickly in recent years. Its size is set to increase from $4.56 billion in 2024 to $5.13 billion in 2025, with a compound annual growth rate (CAGR) of 12.4%. The extension during the historical period is…
Key Influencer in the Hyperphosphatemia Treatment Market 2025: Sustainable Growt …
What industry-specific factors are fueling the growth of the hyperphosphatemia treatment market?
The rise in chronic illnesses among patients is boosting the hyperphosphatemia treatment market. Conditions like cardiovascular and kidney diseases, chronic respiratory conditions, hyperparathyroidism, diabetes, and cancer all fall under the category of chronic diseases, which are non-communicable and demand long-term management. For instance, the World Health Organization reported in September 2023 that 74% of the 41 million global deaths…
Hyperphosphatemia Pipeline Insight Report 2024
(Albany, United States) As per DelveInsight's assessment, globally, the Hyperphosphatemia Pipeline constitutes 15+ key companies continuously working towards developing 15+ Hyperphosphatemia Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Hyperphosphatemia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Hyperphosphatemia NDA approvals (if any), and product development activities comprising…
Hyperphosphatemia Drugs Market to Witness Robust Expansion by 2029
The Hyperphosphatemia Drugs Market size is expected to grow at an annual average of CAGR 2% during the forecast period (2023-2029). Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic uncontrolled diabetes, and low…
